ABLi Therapeutics, Inc., 2026-01-13
An SEC Form D private-offering notice from Atlanta, GA, a $1,000,000 filer-stated offering target in Biotech. Filed 2026-01-13. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Develops small molecule c-Abl kinase inhibitor therapies, led by risvodetinib, for Parkinson's disease and other neurodegenerative disorders.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- Gridline Holdings, Inc., 2026-01-28, $12M, Atlanta, GA
- NexGelRx, Inc., 2026-01-14, $1.2M, Langhorne, PA
- NovAb, Inc., 2026-01-26, $50K, Tucker, GA
- Alveus Therapeutics, Inc., 2026-01-14, $110.7M, Philadelphia, PA
- Posh Outdoors, Inc., 2026-01-14, $750K, Atlanta, GA
- Iaso Therapeutics, Inc., 2026-01-14, $1.8M, East Lansing, MI
- StirlingX Ltd, 2026-01-13, $13.2M, London
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.